Stoke Therapeutics, Inc.

STOK

US86150R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-27 EDT			5-day change	1st Jan Change
13.31 ^USD	+3.02%		-9.82%	+153.04%

06-24	Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to S&P Biotechnology Select Industry Index	CI
06-13	Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders	MT

Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to S&P Biotechnology Select Industry Index

June 23, 2024

Latest news about Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to S&P Biotechnology Select Industry Index	06-23	CI
Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders	06-13	MT
Certain Pre-Funded Warrants of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Certain Common Stock of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.	05-26	CI
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing	05-22	MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating	05-07	MT
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M	05-06	MT
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Stoke Therapeutics Appoints Thomas Leggett CFO	04-29	MT
Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024	04-29	CI
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	04-17	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	03-28	MT
Stoke Therapeutics Prices Upsized $125 Million Share Offering	03-28	MT
North American Morning Briefing : Stocks Edge -2-	03-27	DJ
Stoke Therapeutics Plans $75 Million Public Offering	03-26	MT
Sector Update: Health Care Stocks Advance Late Afternoon	03-26	MT
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients	03-26	MT
Top Midday Gainers	03-26	MT
JPMorgan Adjusts Price Target on Stoke Therapeutics to $13 From $6, Maintains Neutral Rating	03-26	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	03-26	MT
Needham Adjusts Stoke Therapeutics' Price Target to $22 From $14, Maintains Buy Rating	03-26	MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $21 From $18, Keeps Buy Rating	03-26	MT
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	03-26	MT
Top Premarket Gainers	03-26	MT
Wedbush Adjusts Stoke Therapeutics' Price Target to $17 From $13, Keeps Outperform Rating	03-26	MT

Chart Stoke Therapeutics, Inc.

Duration

Period

More charts

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Companyâs initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Stoke Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.31 USD

Average target price

22.14 USD

Spread / Average Target

+66.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
STOKE THERAPEUTICS, INC.	+153.04%	694M
MODERNA, INC.	+21.85%	46.44B
LONZA GROUP AG	+38.73%	39.1B
IQVIA HOLDINGS INC.	-8.05%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.24B
CELLTRION, INC.	-13.75%	25.8B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.9B
MEDPACE HOLDINGS, INC.	+38.43%	13.12B
BIO-TECHNE CORPORATION	-6.92%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.68B

Other Biotechnology & Medical Research